InvestorsHub Logo
Followers 127
Posts 5443
Boards Moderated 0
Alias Born 06/09/2020

Re: exwannabe post# 685222

Monday, 04/15/2024 11:28:04 AM

Monday, April 15, 2024 11:28:04 AM

Post# of 711557
Sad for you then that DCVax-L was the first drug to get the UK PIM designation in 2014.

But don't worry. I will add what you missed, so people can get the full non-fudded narrative.

You're welcome 👍🏻

https://www.prnewswire.com/news-releases/nw-bios-cancer-vaccine-is-the-first-drug-to-be-designated-by-uk-authorities-as-a-promising-innovative-medicine-pim-275263351.html



https://www.gov.uk/government/news/first-uk-promising-innovative-medicine-designation-awarded

CHATGBT

No, the scenario for drugs receiving a Promising Innovative Medicine (PIM) designation is different from the "Specials" program. The PIM designation is part of the Early Access to Medicines Scheme (EAMS) in the UK, which aims to provide patients with faster access to drugs that do not yet have marketing approval but show promise in treating serious or life-threatening conditions. The PIM designation is a step within this scheme that signifies a medicine is a promising candidate for early use based on initial clinical data.

Drugs with PIM designation are indeed intended to go through further clinical development and regulatory review processes toward full marketing approval. The PIM designation facilitates earlier patient access during this development and review process. Thus, unlike the "Specials" program, the PIM scheme is designed as a pathway toward eventual marketing approval for new and innovative drugs, not simply to meet the unique needs of individual patients with existing drugs.

Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News